The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages - PubMed (original) (raw)
. 1993 Dec;23(12):3109-14.
doi: 10.1002/eji.1830231210.
Affiliations
- PMID: 8258324
- DOI: 10.1002/eji.1830231210
The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages
M de Weers et al. Eur J Immunol. 1993 Dec.
Abstract
X-linked agammaglobulinemia (XLA) is an immunodeficiency disease in man, resulting from an arrest in early B cell differentiation. The gene defective in XLA has recently been identified and encodes a cytoplasmic protein tyrosine kinase, named Bruton's tyrosine kinase (btk), essential for cell differentiation and proliferation at the transition from pre-B to later B cell stages. In this study we investigated btk expression by Northern blotting experiments in a series of human (precursor-) B cell lines, acute lymphoblastic leukemias and plasmacytomas. btk was found to be already expressed in very early stages of B cell differentiation, even prior to immunoglobulin (Ig) heavy (H) or light (L) chain gene rearrangements. Transcripts were also detected at the pre-B cell stage and in mature B cells, irrespective of the Ig H chain class expressed. Approximately at the transition from mature B cells to plasma cells, expression of the btk gene is down-regulated. In addition, the btk gene was found to be expressed in myeloid cell lines and acute myeloid leukemias. btk expression in myeloid cells is probably not a prerequisite for myeloid differentiation, since myeloid cells in XLA patients seem not to be affected. No btk expression was found in T-lineage cells. The btk expression profile, i.e. from early precursor-B cell stages preceding Ig rearrangement up to mature B cells, supports the hypothesis that the XLA defect resides in a critical step of B cell development which is independent of the Ig gene recombination machinery.
Similar articles
- Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.
Smith CI, Baskin B, Humire-Greiff P, Zhou JN, Olsson PG, Maniar HS, Kjellén P, Lambris JD, Christensson B, Hammarström L, et al. Smith CI, et al. J Immunol. 1994 Jan 15;152(2):557-65. J Immunol. 1994. PMID: 8283037 - Expression of Bruton's tyrosine kinase protein within the B cell lineage.
Genevier HC, Hinshelwood S, Gaspar HB, Rigley KP, Brown D, Saeland S, Rousset F, Levinsky RJ, Callard RE, Kinnon C, et al. Genevier HC, et al. Eur J Immunol. 1994 Dec;24(12):3100-5. doi: 10.1002/eji.1830241228. Eur J Immunol. 1994. PMID: 7805739 - Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children.
Noordzij JG, de Bruin-Versteeg S, Comans-Bitter WM, Hartwig NG, Hendriks RW, de Groot R, van Dongen JJ. Noordzij JG, et al. Pediatr Res. 2002 Feb;51(2):159-68. doi: 10.1203/00006450-200202000-00007. Pediatr Res. 2002. PMID: 11809909 - Genetic analysis of patients with defects in early B-cell development.
Conley ME, Broides A, Hernandez-Trujillo V, Howard V, Kanegane H, Miyawaki T, Shurtleff SA. Conley ME, et al. Immunol Rev. 2005 Feb;203:216-34. doi: 10.1111/j.0105-2896.2005.00233.x. Immunol Rev. 2005. PMID: 15661032 Review. - Role of Bruton's tyrosine kinase in B cell development.
Maas A, Hendriks RW. Maas A, et al. Dev Immunol. 2001;8(3-4):171-81. doi: 10.1155/2001/28962. Dev Immunol. 2001. PMID: 11785667 Free PMC article. Review.
Cited by
- The genetic theory of infectious diseases: a brief history and selected illustrations.
Casanova JL, Abel L. Casanova JL, et al. Annu Rev Genomics Hum Genet. 2013;14:215-43. doi: 10.1146/annurev-genom-091212-153448. Epub 2013 May 29. Annu Rev Genomics Hum Genet. 2013. PMID: 23724903 Free PMC article. Review. - Novel Bruton's tyrosine kinase inhibitors currently in development.
D'Cruz OJ, Uckun FM. D'Cruz OJ, et al. Onco Targets Ther. 2013;6:161-76. doi: 10.2147/OTT.S33732. Epub 2013 Mar 6. Onco Targets Ther. 2013. PMID: 23493945 Free PMC article. - Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase.
Dingjan GM, Maas A, Nawijn MC, Smit L, Voerman JS, Grosveld F, Hendriks RW. Dingjan GM, et al. EMBO J. 1998 Sep 15;17(18):5309-20. doi: 10.1093/emboj/17.18.5309. EMBO J. 1998. PMID: 9736610 Free PMC article. - The role of Bruton's tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells.
Nündel K, Busto P, Debatis M, Marshak-Rothstein A. Nündel K, et al. J Leukoc Biol. 2013 Nov;94(5):865-75. doi: 10.1189/jlb.0313126. Epub 2013 Jun 26. J Leukoc Biol. 2013. PMID: 23804807 Free PMC article. - Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.
Estupiñán HY, Bouderlique T, He C, Berglöf A, Gupta D, Saher O, Daza Cruz MÁ, Peña-Perez L, Yu L, Zain R, Karlsson MCI, Månsson R, Smith CIE. Estupiñán HY, et al. Blood Adv. 2020 Jun 9;4(11):2439-2450. doi: 10.1182/bloodadvances.2019001319. Blood Adv. 2020. PMID: 32492159 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical